Chemotherapy Use After the RxPONDER Trial

Adjuvant chemotherapy use following the TAILORx and RxPONDER trials in early-stage HR-positive, HER2-negative breast cancer is discussed in this MEDtalk. Jason Jincong Freeman, MPH, MS, PhD Candidate, The University of Chicago, Illinois, USA, highlights increased chemotherapy use among premenopausal women with node-positive disease and a recurrence score of 0–25, a patient group in which the benefit of chemotherapy remains uncertain.